Silexion Therapeutics Corp SEC filings SLXNW
Silexion Therapeutics Corp has 279 filings in SEC EDGAR's recent list, going back to May 9, 2024. Its latest annual report, Form 10-K, was filed on Mar 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 26, 2026 (bylaw or fiscal year change, shareholder vote results). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Oct 19, 2026 | — |
| DEF 14A | Proxy statement | Oct 5, 2026 | Oct 5, 2026 |
| PRE 14A | Preliminary proxy statement | Sep 25, 2026 | Sep 25, 2026 |
| DEFA14A | Additional proxy material | Sep 16, 2026 | — |
| DEFA14A | Additional proxy material | Sep 9, 2026 | — |
| DEF 14A | Proxy statement | Aug 24, 2026 | Aug 24, 2026 |
| PRE 14A | Preliminary proxy statement | Aug 14, 2026 | Aug 14, 2026 |
| DEFA14A | Additional proxy material | Jul 13, 2026 | — |
| DEF 14A | Proxy statement | Jun 16, 2026 | Jun 16, 2026 |
| PRE 14A | Preliminary proxy statement | Jun 3, 2026 | Jun 3, 2026 |
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEF 14A | Proxy statement | Apr 9, 2026 | Apr 9, 2026 |
| PRE 14A | Preliminary proxy statement | Mar 30, 2026 | Mar 30, 2026 |
| DEFA14A | Additional proxy material | Mar 16, 2026 | — |
| DEF 14A | Proxy statement | Feb 23, 2026 | Feb 23, 2026 |
| PRE 14A | Preliminary proxy statement | Feb 13, 2026 | Feb 13, 2026 |
| DEFA14A | Additional proxy material | Aug 12, 2025 | — |
| DEF 14A | Proxy statement | Jul 31, 2025 | Jul 31, 2025 |
| PRE 14A | Preliminary proxy statement | Jul 21, 2025 | Jul 21, 2025 |
| DEFA14A | Additional proxy material | Jul 7, 2025 | — |
| DEFA14A | Additional proxy material | Jun 23, 2025 | — |
| DEF 14A | Proxy statement | Jun 16, 2025 | Jun 16, 2025 |
| PRE 14A | Preliminary proxy statement | Jun 5, 2025 | Jun 5, 2025 |
| DEFA14A | Additional proxy material | Nov 13, 2024 | — |
| DEF 14A | Proxy statement | Oct 22, 2024 | Oct 22, 2024 |
| PRE 14A | Preliminary proxy statement | Oct 10, 2024 | Oct 10, 2024 |
Showing 26 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- SLXN (Nasdaq), SLXNW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Ramat Gan, Israel
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2022416
- Former names
- Biomotion Sciences (until Aug 15, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.